Skip to content

Our science

More than a 100-year experience with drug development and discovery

More than 700 scientists and specialists work within research and development in LEO Pharma to develop new treatments. Together, we take the drugs all the way - from research to registration.
PIPELINE

On our way towards the most innovative pipeline

We offer important standard treatments, as well as new innovative solutions for skin diseases. We have built one of the strongest pipelines in eczema and continue to strengthen our established portfolio
View Our Pipeline
NEWS ARTICLE

LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma

Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 M EUR has been completed.
NEWS ARTICLE

LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825

BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.